The association of antibiotic treatment regimen and hospital mortality in patients hospitalized with legionella pneumonia

Clinical Infectious Diseases

Volumn 60, Issue 11, 2015, Pages e66-e79

  Gershengorn, Hayley B ^a   Keene, Adam ^a   Dzierba, Amy L ^b   Wunsch, Hannah ^b,c,d,e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b New York Presbyterian Hospital ^*  (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

azithromycin; hospital mortality; Legionella; pneumonia; quinolones

Indexed keywords

AZITHROMYCIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG COST; DRUG MEGADOSE; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; LEGIONELLA PNEUMONIA; LEGIONNAIRE DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; YOUNG ADULT; ADOLESCENT; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTION; COLITIS; COMPARATIVE STUDY; COMPLICATION; EPIDEMIOLOGY; LEGIONELLOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; COLITIS; FEMALE; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; LEGIONELLOSIS; LENGTH OF STAY; MALE; MIDDLE AGED; QUINOLONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84930407873     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ157     Document Type: Article

References (50)

1. Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297:1189-97.
2. Adams DA, Gallagher KM, Jajosky RA, et al. Summary of notifiable diseases-United States, 2011. MMWR Morb Mortal Wkly Rep 2013; 60:1-117.
3. Neil K, Berkelman R. Increasing incidence of legionellosis in the United States, 1990-2005: changing epidemiologic trends. Clin Infect Dis 2008; 47:591-9.
4. Benin AL, Benson RF, Besser RE. Trends in Legionnaires disease, 1980- 1998: declining mortality and new patterns of diagnosis. Clin Infect Dis 2002; 35:1039-46.
5. Adams DA, Jajosky RA, Ajani U, et al. Summary of notifiable diseases- United States, 2012. MMWR Morb Mortal Wkly Rep 2014; 61:1-121.
6. New York State Inpatient Database, 2007. Available at: http://www. B-us.ahrq.gov/sidoverview.jsp. Accessed 4 March 2015.
7. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148:1418-26.
8. Saito A, Sawatari K, Fukuda Y, et al. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother 1985; 28:15-20.
9. Saito A, Koga H, Shigeno H, et al. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother 1986; 18:251-60.
10. Dournon E, Rajagopalan P, Vilde JL, Pocidalo JJ. Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J Antimicrob Chemother 1986; 17(suppl B): 41-8.
11. Tzianabos AO, Rodgers FG. Pathogenesis and chemotherapy of experimental Legionella pneumophila infection in the chick embryo. Zentralbl Bakteriol 1989; 271:293-303.
12. Edelstein PH, Edelstein MA, Weidenfeld J, Dorr MB. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1990; 34:2122-7.
13. García-de-Lomas J, Millás E, Lázaro MA, et al. A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs. Eur J Clin Microbiol Infect Dis 1998; 17:420-3.
14. Edelstein PH, Shinzato T, Doyle E, Edelstein MA. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001; 45:2204-9.
15. Fitzgeorge RB, Featherstone AS, Baskerville A. Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol. J Antimicrob Chemother 1990; 25(suppl A):101-8.
16. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J Antimicrob Chemother 1993; 31(suppl E): 171-6.
17. Stout JE, Arnold B, Yu VL. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells. J Antimicrob Chemother 1998; 41:289-91.
18. Sabrià M, Pedro-Botet ML, Gómez J, et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128:1401-5.
19. Mykietiuk A, Carratalà J, Fernández-Sabé N, et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40: 794-9.
20. Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L, et al. Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40:800-6.
21. Falcó V, Molina I, Juste C, et al. Treatment for Legionnaires' disease. B or quinolones? [in Spanish]. Enferm Infecc Microbiol Clin 2006; 24:360-4.
22. Haranaga S, Tateyama M, Higa F, et al. Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia. Intern Med 2007; 46:353-7.
23. Griffin AT, Peyrani P, Wiemken T, Arnold F. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study. Int J Tuberc Lung Dis 2010; 14:495-9.
24. Viasus D, Di Yacovo S, Garcia-Vidal C, et al. Community-acquired Legionella pneumophila pneumonia: a single-center experience with 214 hospitalized sporadic cases over 15 years. Medicine (Baltimore) 2013; 92:51-60.
25. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(suppl 2):S27-72.
26. Pedro-Botet ML, Yu VL. Treatment strategies for Legionella infection. B Opin Pharmacother 2009; 10:1109-21.
27. Premier, Inc. Premier Research Services. Available at: https://www. B.com/transforming-healthcare/healthcare-performanceimprovement/ premier-research-services/. Accessed 7 January 2015.
28. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36:8-27.
29. Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA 2010; 303:2359-67.
30. Shaw AD, Bagshaw SM, Goldstein SL, et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann Surg 2012; 255:821-9.
31. Rothberg MB, Pekow PS, Priya A, et al. Using highly detailed administrative data to predict pneumonia mortality. PLoS One 2014; 9:e87382.
32. Ng V, Tang P, Jamieson F, Guyard C, Low DE, Fisman DN. Laboratorybased evaluation of legionellosis epidemiology in Ontario, Canada, 1978 to 2006. BMC Infect Dis 2009; 9:68.
33. Bradley JS, Byington CL, Shah SS, et al. The management of community- acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25-76.
34. Lindenauer PK, Stefan MS, Johnson KG, Priya A, Pekow PS, Rothberg MB. Prevalence, treatment, and outcomes associated with OSA among patients hospitalized with pneumonia. Chest 2014; 145:1032-8.
35. Scheurer DB, Hicks LS, Cook EF, Schnipper JL. Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort. Epidemiol Infect 2007; 135:1010-3.
36. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol 2006; 163:1149-56.
37. Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002; 123:8-15.
38. Smith JA, Todd PE. Does matching overcome LaLonde's critique of nonexperimental estimators? J Econometrics 2005; 125:305-53.
39. Marrie RA, Dawson NV, Garland A. Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. J Clin Epidemiol 2009; 62:511-7.e1.
40. Lunt M. pbalchk: Stata module for checking the balancing of the covariates between two groups. Availale at: http://personalpages.manchester. B.uk/staff/mark.lunt/propensity.html. Accessed 14 November 2013.
41. Leuven E, Sianesi B. psmatch2: Stata module which implements full Mahalanobis matching and a variety of propensity score matching methods to adjust for pre-treatment observable differences between a group of treated and a group of untreated. Available at: http://ideas. B.org/c/boc/bocode/s432001.html. Accessed 14 November 2013.
42. Fields BS, Benson RF, Besser RE. Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002; 15:506-26.
43. Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med 1998; 129:328-30.
44. Roig J, Rello J. Legionnaires' disease: a rational approach to therapy. B Antimicrob Chemother 2003; 51:1119-29.
45. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridiumdifficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254-60.
46. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005; 26:680-4.
47. Modena S, Bearelly D, Swartz K, Friedenberg FK. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect Control Hosp Epidemiol 2005; 26:685-90.
48. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. B difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 45:1543-9.
49. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. B Control Hosp Epidemiol 2008; 29:44-50.
50. Ye X, Sikirica V, Schein JR, et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008; 30:358-71.